Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07332468

Digital Remote Management for Care and Continuous Optimization Versus Usual Care to Reduce Risk of Atherosclerotic Cardiovascular Diseases (DigiCare-ASCVD)

The DigiCare-ASCVD study is an investigator-initiated, multicenter, open-label, parallel-group randomized controlled trial. It aims to evaluated whether digital remote management is superior to usual care in reducing risk of atherosclerotic cardiovascular diseases and improving blood pressure control, glycemic control, lipids control, medication compliance and lifestyle.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

35 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Beijing Anzhen Hospital, Capital Medical University, Beijing, China, Beijing, China

Loading trial locations.

About this study

"Atherosclerotic cardiovascular disease (ASCVD) is a leading global cause of mortality. Primary care is central to its prevention within tiered healthcare systems, yet faces challenges including physician training gaps and inefficient specialist referrals. Digital remote interventions offer a promising solution due to widespread smartphone/internet access, enabling convenient care and real-time data use. Current tools focus on patient education/reminders or clinical decision support (CDSS) separately. However, effective long-term ASCVD management requires an integrated system that combines CDSS-guided treatment with comprehensive, sustained risk-factor monitoring (e.g., blood pressure, lipids). This study aims to develop and validate such an integrated remote management platform to overcome multi-level barriers, disseminate advanced resources to primary care, and enhance equitable cardiovascular risk prevention.

The DigiCare-ASCVD Study is a multicenter, open-label, randomized controlled trial with a 1:1 parallel-group design. It will enroll 790 patients at high risk for ASCVD. All enrolled patients will be randomly assigned in a 1:1 ratio to either the Digital Remote Management group or the usual care group.

Patients in the Digital Remote Management group will utilize a smartphone-based ""physician-machine collaboration"" platform. This system integrates home monitoring to track BP, lipids,glucose, medication compliance and physical activity. It features AI-driven alerts for abnormal values, automated medication adjustment suggestions (verified by physicians), and targeted health education The primary endpoint is the mean change in the patient's 10-year ASCVD risk, calculated using the China-PAR risk prediction model, from baseline to the 12-month follow-up."

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 10-year ASCVD risk ≥ 10%, calculated using the China-PAR risk prediction model
  • Adultd aged ≥ 35 years
  • Able to use a smartphone (or assisted by family) and agrees to remote management
  • Signed informed consent

Exclusion criteria

  • History of acute myocardial infarction, stroke, heart failure, malignant arrhythmia, or prior percutaneous coronary intervention or coronary artery bypass grafting surgery
  • Moderate to severe hepatic dysfunction (Child-Pugh class B-C)
  • CKD stages 4-5 (eGFR <30 ml/min/1.73m²) or on dialysis
  • Chronic obstructive pulmonary disease requiring ongoing home oxygen therapy or chronic oral steroid therapy as an outpatient
  • Pregnant, planning to become pregnant within the next 12 months
  • Life expectancy <12 months (e.g., advanced malignancy, etc.);
  • Cognitive impairment or communication disorder.

Treatment and study plan

Digital Remote Management Group

Other

In addition to usual care, patients receive a 1-year intervention via a smartphone-based ""physician-machine collaboration"" platform:

  • BP Management: Daily or weekly self-monitoring based on control status. System triggers alerts for BP >130/80 mmHg and generates medication adjustment suggestions for physician approval.
  • Lipid Management: Reminder for lab tests. OCR technology parses results. If LDL-C ≥2.6 mmol/L, the system suggests regimen intensification for physician review.
  • Blood Glucose Management: Reminder for lab tests. OCR technology parses results.If Fasting Blood Glucose (FBG) ≥6.1 mmol/L for patients without diabetes and FBG ≥7.0 mmol/L for patients with diabetes, the system suggests regimen intensification for physician review.
  • Medication Management: Daily app-based reminders and clock-in tasks. Non-adherence triggers automated reminders and human follow-up.
  • Health Education: Regular push of targeted articles/videos on secondary prevention。

Primary outcomes

  1. Mean change in the patient's 10-year ASCVD risk, calculated using the China-PAR risk prediction model

    Time frame: 12 Months

Secondary outcomes

  1. Mean change in the patient's lifetime ASCVD risk, calculated using the China-PAR risk prediction model.

    Time frame: Baseline and 12 Months

  2. Simultaneous Control Rate of Blood Pressure

    Time frame: 12 Months

    SBP < 130 mmHg, DBP < 80 mmHg

  3. Mean change in SBP and DBP compared to baseline

    Time frame: 12 Months

  4. Overweight or Obesity Rate

    Time frame: 12 Months

  5. Smoking Cessation Rate

    Time frame: 12 Months

    Self-reported complete abstinence from smoking among baseline smokers

  6. Medication Adherence

    Time frame: 12 Months

    MARS-10 scale

Study contacts

Contact information is provided by the study sponsor or research team.

Sponsors and collaborators

Lead sponsor

Beijing Anzhen Hospital

Other

Registry information

Acronym: DigiCare-ASCVD

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jan 12, 2026
Registry last updated
Jan 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.